Theriva Biologics Stock Forecast for 2023 - 2025 - 2030
Updated on 04/25/2024
Theriva Biologics Stock Forecast and Price Target
According to experts, who recently provided their 2024 price targets for Theriva Biologics, the average price target is $4.50, with a high estimate of $7.00 and a low estimate of $2.00. That is a potential upside of approximately 1116.22% from the last closing price of $0.37 on April, 2024. Even if not interested in TOVX stock, you may want to be aware of its competitors.
1116.22% Upside
Theriva Biologics Fair Value Forecast for 2023 - 2025 - 2030
In the last three years, Price for Theriva Biologics has grown by 100.00%, going from $0.00 to $0.00. In the coming year, analysts are expecting an increase in Fair Value, predicting it will reach $0.40 – an increase of 100.00%. Over the next seven years, experts anticipate that Fair Value growth for Theriva Biologics will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| LLY Stock Forecast | Eli Lilly and | Outperform |
16
|
$732.20 | Buy/Sell | $636.99 | 14.38% |
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$148.53 | Buy/Sell | $174.55 | 14.45% |
| MRK Stock Forecast | Merck | Outperform |
2
|
$127.00 | Buy/Sell | $130.51 | 9.84% |
| PFE Stock Forecast | Pfizer | Outperform |
2
|
$26.27 | Buy/Sell | $32.87 | 16.10% |
| VRTX Stock Forecast | Vertex Pharmaceuticals Inc | Outperform |
12
|
$400.76 | Buy/Sell | $457.59 | 12.29% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BMY Stock Forecast | Bristol-Myers Squibb | Hold |
2
|
$48.86 | Buy/Sell | $58.15 | 12.57% |
| REGN Stock Forecast | Regeneron Pharmaceuticals | Outperform |
2
|
$906.54 | Buy/Sell | $961.26 | 15.83% |
| ZTS Stock Forecast | Zoetis | Outperform |
18
|
$150.88 | Buy/Sell | $220.47 | 46.47% |
.jpg)
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$40.93 | Buy/Sell | $44.86 | 9.94% |
| ALNY Stock Forecast | Alnylam Pharmaceuticals Inc | Outperform |
7
|
$143.80 | Buy/Sell | $245.24 | 49.51% |
| VTRS Stock Forecast | Viatris Inc | Hold |
8
|
$11.55 | Buy/Sell | $11.73 | 3.90% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| UTHR Stock Forecast | United Therapeutics | Outperform |
12
|
$237.00 | Buy/Sell | $284.08 | 25.32% |
| CTLT Stock Forecast | Catalent | Hold |
15
|
$55.95 | Buy/Sell | $49.29 | 13.49% |
| CYTK Stock Forecast | Cytokinetics | Outperform |
10
|
$66.82 | Buy/Sell | $87.92 | 40.68% |
Theriva Biologics EBITDA Forecast for 2023 - 2025 - 2030
In the last two years, Theriva Biologics's EBITDA has grown, increasing from $-9.96M to $-21.50M – an increase of 115.86%. According to 0 major analysts, Theriva Biologics's EBITDA will fall by 32.60% in the next year, reaching $-14.49M. Professionals believe that By 2030, Theriva Biologics's EBITDA will fall to $-15.76M– a 26.68% decrease from its current value.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| IONS Stock Forecast | Ionis Pharmaceuticals | Outperform |
9
|
$42.45 | Buy/Sell | $55.60 | 41.81% |
| MDGL Stock Forecast | Madrigal Pharmaceuticals | Outperform |
4
|
$204.65 | Buy/Sell | $315.92 | 90.57% |
| BCPC Stock Forecast | Balchem | Outperform |
18
|
$140.64 | Buy/Sell | $145.00 | 15.90% |
Theriva Biologics EBIT Forecast for 2023 - 2025 - 2030
Theriva Biologics's EBIT has increased by 112.40% In the last two years, going from $-10.16M to $-21.58M. In the next year, analysts expect EBIT to reach $-28.21M – an increase of 30.72%. According to professional forecasts, in 2030, Theriva Biologics's EBIT will decrease by 902.69%, reaching $173.22M.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| PRGO Stock Forecast | Perrigo Co PLC | Outperform |
16
|
$31.23 | Buy/Sell | $44.75 | 26.80% |
| NEOG Stock Forecast | Neogen | Outperform |
16
|
$12.37 | Buy/Sell | $37.00 | 37.43% |
| INDV Stock Forecast | Indivior PLC | Buy |
14
|
£15.14 | Buy/Sell | £28.89 | 108.06% |
Theriva Biologics EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last three years, EPS for Theriva Biologics has grown by 100.00%, going from $-1.90 to $0.00. In the coming year, analysts are expecting an increase in EPS, predicting it will reach $-0.87 – an increase of 100.00%. Over the next seven years, experts anticipate that EPS growth for Theriva Biologics will be 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CORT Stock Forecast | Corcept Therapeutics | Buy |
16
|
$22.48 | Buy/Sell | $35.67 | 69.04% |
| IRWD Stock Forecast | Ironwood Pharmaceuticals | Buy |
14
|
$8.10 | Buy/Sell | $17.83 | 109.88% |
| TGTX Stock Forecast | TG Therapeutics | Outperform |
9
|
$13.98 | Buy/Sell | $29.44 | 143.20% |
.jpg)